AIMS: Spindle-cell/sclerosing rhabdomyosarcomas (SS-RMS) are clinically and genetically heterogeneous. They include three well-defined molecular subtypes, of which those with EWSR1/FUS::TFCP2 rearrangements were described only recently. This study aimed to evaluate five new cases of SS-RMS and to perform a clinicopathological and statistical analysis of all TFCP2-rearranged SS-RMS described in the English literature to more comprehensively characterize this rare tumour type. METHODS AND RESULTS: Cases were retrospectively selected and studied by immunohistochemistry, fluorescence in situ hybridization with EWSR1/FUS and TFCP2 break-apart probes, next-generation sequencing (Archer FusionPlex Sarcoma kit and TruSight RNA Pan-Cancer Panel). The PubMed database was searched for relevant peer-reviewed English reports. Five cases of SS-RMS were found. Three cases were TFCP2 rearranged SS-RMS, having FUSex6::TFCP2ex2 gene fusion in two cases and triple gene fusion EWSR1ex5::TFCP2ex2, VAX2ex2::ALKex2 and VAX2intron2::ALKex2 in one case. Two cases showed rhabdomyoblastic differentiation and spindle-round cell/sclerosing morphology, but were characterized by novel genetic fusions including EWSR1ex8::ZBTB41ex7 and PLOD2ex8::RBM6ex7, respectively. In the statistical analysis of all published cases, CDKN2A or ALK alterations, the use of standard chemotherapy and age at presentation in the range of 18-24 years were negatively correlated to overall survival. CONCLUSION: EWSR1/FUS::TFCP2-rearranged SS-RMS is a rare rhabdomyosarcoma subtype, affecting predominantly young adults with average age at presentation 34 years (median 29.5 years; age range 7-86 years), with a predilection for craniofacial bones, rapid clinical course with frequent bone and lung metastases, and poor prognosis (3-year overall survival rate 28%).

Bioptic Laboratory Ltd Plzen Czech Republic

Cytopathos Ltd Bratislava Slovakia

Department of Pathology Faculty of Medicine in Plzen Charles University Prague Czech Republic

Department of Pathology Třinec Hospital Třinec Czech Republic

Division of Information Technologies and Statistics Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Medical Laboratory CSD Kyiv Ukraine

Medicyt Ltd Košice Slovakia

Onco Team Diagnostic București Romania

Unilabs Diagnostic Pathology Centre Prešov Slovakia

000      

00000naa a2200000 a 4500

001      

bmc24006602

003      

CZ-PrNML

005      

20240423155401.0

007      

ta

008      

240412s2024 enk f 000 0|eng||

009      

AR

024    7_

$a 10.1111/his.15121 $2 doi

035    __

$a (PubMed)38114270

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a enk

100    1_

$a Bradová, Martina $u Department of Pathology, Faculty of Medicine in Plzen, Charles University, Prague, Czech Republic $u Bioptic Laboratory Ltd, Plzen, Czech Republic $1 https://orcid.org/0000000258295572

245    10

$a Spindle cell rhabdomyosarcomas: With TFCP2 rearrangements, and novel EWSR1::ZBTB41 and PLOD2::RBM6 gene fusions. A study of five cases and review of the literature / $c M. Bradová, E. Mosaieby, M. Michal, T. Vaněček, SK. Ing, P. Grossmann, O. Koshyk, Z. Kinkor, Š. Laciok, A. Nemcová, Ľ. Straka, M. Farkas, M. Michal, M. Švajdler

520    9_

$a AIMS: Spindle-cell/sclerosing rhabdomyosarcomas (SS-RMS) are clinically and genetically heterogeneous. They include three well-defined molecular subtypes, of which those with EWSR1/FUS::TFCP2 rearrangements were described only recently. This study aimed to evaluate five new cases of SS-RMS and to perform a clinicopathological and statistical analysis of all TFCP2-rearranged SS-RMS described in the English literature to more comprehensively characterize this rare tumour type. METHODS AND RESULTS: Cases were retrospectively selected and studied by immunohistochemistry, fluorescence in situ hybridization with EWSR1/FUS and TFCP2 break-apart probes, next-generation sequencing (Archer FusionPlex Sarcoma kit and TruSight RNA Pan-Cancer Panel). The PubMed database was searched for relevant peer-reviewed English reports. Five cases of SS-RMS were found. Three cases were TFCP2 rearranged SS-RMS, having FUSex6::TFCP2ex2 gene fusion in two cases and triple gene fusion EWSR1ex5::TFCP2ex2, VAX2ex2::ALKex2 and VAX2intron2::ALKex2 in one case. Two cases showed rhabdomyoblastic differentiation and spindle-round cell/sclerosing morphology, but were characterized by novel genetic fusions including EWSR1ex8::ZBTB41ex7 and PLOD2ex8::RBM6ex7, respectively. In the statistical analysis of all published cases, CDKN2A or ALK alterations, the use of standard chemotherapy and age at presentation in the range of 18-24 years were negatively correlated to overall survival. CONCLUSION: EWSR1/FUS::TFCP2-rearranged SS-RMS is a rare rhabdomyosarcoma subtype, affecting predominantly young adults with average age at presentation 34 years (median 29.5 years; age range 7-86 years), with a predilection for craniofacial bones, rapid clinical course with frequent bone and lung metastases, and poor prognosis (3-year overall survival rate 28%).

650    _2

$a mladý dospělý $7 D055815

650    _2

$a dítě $7 D002648

650    _2

$a lidé $7 D006801

650    _2

$a dospělí $7 D000328

650    _2

$a mladiství $7 D000293

650    _2

$a lidé středního věku $7 D008875

650    _2

$a senioři $7 D000368

650    _2

$a senioři nad 80 let $7 D000369

650    _2

$a hybridizace in situ fluorescenční $7 D017404

650    _2

$a retrospektivní studie $7 D012189

650    12

$a transkripční faktory $x genetika $7 D014157

650    _2

$a protein EWS vázající RNA $x genetika $7 D034802

650    12

$a rhabdomyosarkom $x genetika $x patologie $7 D012208

650    _2

$a fúze genů $7 D050939

650    _2

$a nádorové biomarkery $x genetika $7 D014408

650    _2

$a proteiny vázající RNA $x genetika $7 D016601

650    _2

$a lysinhydroxylasa $x genetika $7 D008240

650    _2

$a DNA vazebné proteiny $x genetika $7 D004268

655    _2

$a přehledy $7 D016454

655    _2

$a časopisecké články $7 D016428

700    1_

$a Mosaieby, Elaheh $u Department of Pathology, Faculty of Medicine in Plzen, Charles University, Prague, Czech Republic $u Bioptic Laboratory Ltd, Plzen, Czech Republic

700    1_

$a Michal, Michael $u Department of Pathology, Faculty of Medicine in Plzen, Charles University, Prague, Czech Republic $u Bioptic Laboratory Ltd, Plzen, Czech Republic

700    1_

$a Vaněček, Tomáš $u Bioptic Laboratory Ltd, Plzen, Czech Republic

700    1_

$a Ing, Stanislav Kormunda $u Division of Information Technologies and Statistics, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic

700    1_

$a Grossmann, Petr $u Bioptic Laboratory Ltd, Plzen, Czech Republic

700    1_

$a Koshyk, Olena $u Medical Laboratory CSD, Kyiv, Ukraine

700    1_

$a Kinkor, Zdeněk $u Department of Pathology, Faculty of Medicine in Plzen, Charles University, Prague, Czech Republic $u Bioptic Laboratory Ltd, Plzen, Czech Republic

700    1_

$a Laciok, Šimon $u Department of Pathology, Třinec Hospital, Třinec, Czech Republic

700    1_

$a Nemcová, Antónia $u Medicyt Ltd, Košice, Slovakia

700    1_

$a Straka, Ľubomír $u Unilabs, Diagnostic Pathology Centre, Prešov, Slovakia

700    1_

$a Farkas, Mihaela $u Onco Team Diagnostic, București, Romania

700    1_

$a Michal, Michal $u Department of Pathology, Faculty of Medicine in Plzen, Charles University, Prague, Czech Republic $u Bioptic Laboratory Ltd, Plzen, Czech Republic

700    1_

$a Švajdler, Marián $u Department of Pathology, Faculty of Medicine in Plzen, Charles University, Prague, Czech Republic $u Bioptic Laboratory Ltd, Plzen, Czech Republic $u Cytopathos, Ltd, Bratislava, Slovakia

773    0_

$w MED00002043 $t Histopathology $x 1365-2559 $g Roč. 84, č. 5 (2024), s. 776-793

856    41

$u https://pubmed.ncbi.nlm.nih.gov/38114270 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y - $z 0

990    __

$a 20240412 $b ABA008

991    __

$a 20240423155358 $b ABA008

999    __

$a ok $b bmc $g 2080917 $s 1216369

BAS    __

$a 3

BAS    __

$a PreBMC-MEDLINE

BMC    __

$a 2024 $b 84 $c 5 $d 776-793 $e 20231219 $i 1365-2559 $m Histopathology $n Histopathology $x MED00002043

LZP    __

$a Pubmed-20240412